Actively Recruiting

Phase 1
Age: 30Years - 70Years
All Genders
NCT07050173

Monitoring Patients With Repetitive Head Impact With Gamma-glutamylcysteine Supplementation

Led by Pravat Mandal · Updated on 2026-04-09

30

Participants Needed

1

Research Sites

90 weeks

Total Duration

On this page

Sponsors

P

Pravat Mandal

Lead Sponsor

C

Chuck Noll Foundation

Collaborating Sponsor

AI-Summary

What this Trial Is About

The goal of this clinical trial is to test whether the gamma - glutamylcystiene (GGC) oral supplement can reach the brain and subsequently increase antioxidant glutathione (GSH) level in people with repetitive head impact (RHI). This will reduce the oxidative stress related injury in people with RHI.This unique study's main objective is to test the: 1. Change in GSH in brain and blood levels through GGC supplementation. 2. Change in the cognitive function in RHI patients due to GGC supplementation.

CONDITIONS

Official Title

Monitoring Patients With Repetitive Head Impact With Gamma-glutamylcysteine Supplementation

Who Can Participate

Age: 30Years - 70Years
All Genders

Eligibility Criteria

Eligible

You may qualify if you...

  • Retired NFL player, retired Navy SEAL, or army personnel with combat experience exposed to repetitive head impact
  • Self- or informant-reported memory or behavioral complaints
  • Age between 30 and 70 years
  • Able to read, write English, and give consent to participate
Not Eligible

You will not qualify if you...

  • Presence of pacemakers, aneurysm clips, artificial heart valves, ear implants, or metal fragments in the eyes, skin, or body
  • Claustrophobia
  • Mild cognitive impairment defined by TICS score 29 or lower or 1 or more standard deviations below age expectation on two or more cognitive tests in the same domain
  • History of cancer
  • Active psychosis or delirium
  • Chronic kidney disease (creatinine > 1.5 mg/dL) or liver disease (AST or ALT ≥ 1.5 times upper limit of normal) within 30 days before enrollment
  • Use of antioxidant therapy (gingko biloba or N-acetylcysteine) or illicit drug abuse/dependence
  • Neurosurgical intervention due to repeated head injury
  • Repeated head injury within the last 90 days

AI-Screening

AI-Powered Screening

Complete this quick 3-step screening to check your eligibility

1
2
3
+1

Trial Site Locations

Total: 1 location

1

UPMC Presbyterian Hospital

Pittsburgh, Pennsylvania, United States, 15213

Actively Recruiting

Loading map...

Research Team

P

Pravat K MANDAL, PHD

CONTACT

How is the study designed?

Study Type

INTERVENTIONAL

Masking

NONE

Allocation

NA

Model

SINGLE_GROUP

Primary Purpose

PREVENTION

Number of Arms

1

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here